HRT Tablets or Patches?

An HRT tablet can contain estrogen alone or estrogen with a progestogen. Patches also come as estrogen-only or combined products. The first question is whether the proposed medicine includes all the hormones you need, with a schedule suited to your menstrual stage.

Gel and spray are additional transdermal options. Low-dose vaginal estrogen serves a different purpose, treating local vaginal symptoms with much lower systemic exposure. It is not a substitute for systemic treatment when hot flashes need treatment.

NICE recommends considering transdermal treatment for people at increased risk of venous thromboembolism, including those with a BMI over 30. VTE includes deep vein thrombosis and pulmonary embolism. A previous clot or a hereditary clotting disorder requires more detailed assessment.

A lower route-related risk does not override the product's contraindications. The cited US estradiol patch label lists previous or active DVT or pulmonary embolism, stroke or heart attack history, breast cancer, liver disease, and certain thrombophilias among its contraindications. A patch cannot be assumed suitable simply because an oral product is unsuitable.

Oral estrogen also has a higher gallbladder-risk profile in ACOG's patient guidance. Breast and endometrial cancer risk need a separate review of the hormone combination and duration; changing estrogen route does not settle those questions.

The cited twice-weekly estradiol label directs application to clean, dry skin on the lower abdomen or buttocks, avoiding the breasts. Its instructions also describe site rotation and what to do if a patch loosens or falls off. Other products can have a different change schedule or application instructions.

Ask the pharmacist to demonstrate the exact patch. Check where to apply it, when to change it, and how to handle a detached patch. Follow that leaflet for bathing, skin products, and replacement. A patch that repeatedly fails to stick needs a review of use or the product.

Record skin redness, itching, or other local effects. A different patch, gel, or spray may be considered, depending on the assessment. Avoid adding patches or changing frequency to compensate for symptoms without speaking to the prescriber.

With a uterus, systemic estrogen usually needs adequate progestogen protection to reduce endometrial overgrowth and cancer risk. An estrogen-only patch supplies no progestogen. The prescription may therefore include a separate tablet, a combined product, or another appropriate plan.

Continuous and cyclic regimens have different schedules and expected bleeding patterns. A switch from a combined tablet to an estrogen-only patch should explicitly state how progestogen will be supplied. Do not assume that it can be omitted because the estrogen dose or route has changed.

If oral progesterone causes tiredness, dizziness, or mood effects, describe those to the prescriber. Changing estrogen route alone may leave that problem unresolved. The cited progesterone capsule label advises bedtime dosing and contains peanut oil, which matters for allergy assessment.

Milligram doses in tablets and daily delivery amounts on patches are not directly interchangeable. The prescriber should select the replacement using the exact products, symptom response, side effects, and safety history. A switch may be prompted by risk, tolerance, or convenience.

• Confirm the last dose or application of the old product and the start of the new one.
• Write down the patch-change or tablet schedule and the progestogen plan.
• Ask what bleeding pattern to expect and when to contact the team.
• Record symptoms and adverse effects so the next review can judge the change.

Unscheduled bleeding can occur after a change, but persistent or concerning bleeding needs assessment. NICE advises prompt medical help when it continues beyond three months after a systemic HRT change. Heavy bleeding warrants earlier contact.

Review other medicines at the same time

Tell the prescriber about thyroid treatment and any new medicines, including semaglutide or tirzepatide. GLP-1 treatments can complicate oral medication routines through delayed stomach emptying or digestive effects. If estrogen is changed to a patch but progesterone remains oral, that part of the regimen still needs review.